Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile

Author(s): Sukhes Mukherjee* and Suman Kumar Ray

Volume 22, Issue 4, 2022

Published on: 28 March, 2022

Article ID: e170122200309 Pages: 3

DOI: 10.2174/1871526522666220117153838

conference banner
Abstract

Herd immunity can only be achieved when it is extended to the population level. When a sufficiently significant fraction of immune individuals exists in a group, it confers indirect protection from infection to vulnerable individuals. This population-level effect is frequently considered in the context of vaccination programs, which attempt to build herd immunity so that people who cannot be vaccinated, such as the very young or those with impaired immune systems, are nonetheless protected from disease. Clinical signs are at times poor predictor of transmissibility for some infections, such as COVID-19, because asymptomatic hosts can be extremely infectious and contribute to the spread of the virus. COVID-19 is a quickly evolving issue that has been widely spread throughout the world. This article elaborates the idea and goal of herd immunity, the necessary conditions for realizing herd immunity, the restrictive requirements for applying herd immunity, and the obstacles experienced in achieving herd immunity in the context of COVID-19. This mini-article explains the concept and purpose of herd immunization in the context of COVID-19.

Keywords: Herd immunity, COVID-19, vaccination, SARS-CoV-2 infection, global populations.

[1]
Ray SK, Mukherjee S. Understanding the role of corona virus based on current scientific evidence - a review with emerging importance in pandemic. Recent Pat Antiinfect Drug Discov 2020; 15(2): 89-103.
[http://dx.doi.org/10.2174/1574891X15999200918144833] [PMID: 32957894]
[2]
Hossain MS, Hami I, Sawrav MSS, et al. Drug repurposing for prevention and treatment of covid-19: A clinical landscape. Discoveries (Craiova) 2020; 8(4): e121.
[http://dx.doi.org/10.15190/d.2020.18] [PMID: 33403227]
[3]
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 2021; 6(1): 28.
[http://dx.doi.org/10.1038/s41541-021-00292-w] [PMID: 33619260]
[4]
Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 40.
[http://dx.doi.org/10.1186/s13578-020-00404-4] [PMID: 32190290]
[5]
Randolph HE, Barreiro LB. Herd immunity: Understanding COVID-19. Immunity 2020; 52(5): 737-41.
[http://dx.doi.org/10.1016/j.immuni.2020.04.012] [PMID: 32433946]
[6]
van den Driessche P. Reproduction numbers of infectious disease models. Infect Dis Model 2017; 2(3): 288-303.
[http://dx.doi.org/10.1016/j.idm.2017.06.002] [PMID: 29928743]
[7]
Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the basic reproduction number (R0). Emerg Infect Dis 2019; 25(1): 1-4.
[http://dx.doi.org/10.3201/eid2501.171901] [PMID: 30560777]
[8]
Jabbar SI. Automated analysis of fatality rates for COVID 19 across different countries. Alex Eng J 2021; 60(1): 521-6.
[http://dx.doi.org/10.1016/j.aej.2020.09.027]
[9]
Kuster AC, Overgaard HJ. A novel comprehensive metric to assess effectiveness of COVID-19 testing: Inter-country comparison and association with geography, government, and policy response. PLoS One 2021; 16(3): e0248176.
[http://dx.doi.org/10.1371/journal.pone.0248176] [PMID: 33667280]
[10]
Tanase C, Albulescu R, Neagu M. Understanding COVID-19 immunity: reality and challenges. J Immunoassay Immunochem 2020; 41(6): 925-7.
[http://dx.doi.org/10.1080/15321819.2020.1864743] [PMID: 33350881]
[11]
Omer SB, Yildirim I, Forman HP. Herd immunity and implications for SARS-CoV-2 control. JAMA 2020; 324(20): 2095-6.
[http://dx.doi.org/10.1001/jama.2020.20892] [PMID: 33074293]
[12]
Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA 2020; 323(22): 2245-6.
[http://dx.doi.org/10.1001/jama.2020.7869] [PMID: 32391855]
[13]
Clemente-Suárez VJ, Hormeño-Holgado A, Jiménez M, et al. Dynamics of population immunity due to the herd effect in the COVID-19 pandemic. Vaccines (Basel) 2020; 8(2): 236.
[http://dx.doi.org/10.3390/vaccines8020236] [PMID: 32438622]
[14]
Martins IJ. Covid-19 infection and anti-aging gene inactivation. Acta Scientific Nutritional Health 2020; 4.5: 01-2.
[15]
Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA 2020; 323(24): 2458-9.
[http://dx.doi.org/10.1001/jama.2020.8711] [PMID: 32421155]
[16]
Xia Y, Zhong L, Tan J, et al. How to understand “herd immunity” in covid-19 pandemic. Front Cell Dev Biol 2020; 8: 547314.
[http://dx.doi.org/10.3389/fcell.2020.547314] [PMID: 33072741]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy